Tibet AIM Pharm Valuation

Q: What is the Fair Price of 002826 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002826 (CN¥12.18) is trading below our estimate of [[fair value]] (CN¥46.27)

Is 002826 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002826 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002826 (CN¥12.18) is trading below our estimate of fair value (CN¥46.27)

Significantly Below Fair Value: 002826 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002826?

Key metric: As 002826 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002826. This is calculated by dividing 002826's market cap by their current earnings.
What is 002826's PE Ratio?
PE Ratio	67.1x
Earnings	CN¥33.32m
Market Cap	CN¥2.23b

002826 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.9x
Enterprise Value/EBITDA	24.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 002826's PE Ratio compare to its peers?

The above table shows the PE ratio for 002826 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	42.3x
002873 Guiyang Xintian PharmaceuticalLtd	40.2x	28.5%	CN¥2.2b
301130 Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd	47.3x	n/a	CN¥2.0b
300254 ShanXi C&Y Pharmaceutical GroupLTD	28.2x	n/a	CN¥2.3b
300519 Zhejiang Xinguang Pharmaceutical	53.3x	n/a	CN¥2.3b
002826 Tibet AIM Pharm	67.1x	n/a	CN¥2.2b

Price-To-Earnings vs Peers: 002826 is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the peer average (42.3x).

Price to Earnings Ratio vs Industry

How does 002826's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002826 is expensive based on its Price-To-Earnings Ratio (67.1x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 002826's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002826 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	67.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 002826's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%